期刊文献+

他喷他多治疗慢性非癌性疼痛的有效性和安全性Meta分析

原文传递
导出
摘要 目的采用Meta分析法综合评价他喷他多治疗慢性非癌性疼痛的有效性和安全性.方法检索CochraneLibrary、PubMed、ScienceDirect、FDA等数据库及中国期刊全文数据库和万方数据库,采用改良版Jadad法评价纳入的文献质量.以总体反应有效率、数字疼痛评分(NRS)均分变化和治疗突发不良事件(Treatment-emergentadverseevents,TEAEs)及终止率为主要评价指标,应用Stata12.0软件对有关他喷他多治疗慢性非癌性疼痛的随机对照试验研究文献进行Meta分析.结果共检出文献39篇,符合标准6篇纳入Meta分析,共包括4799例患者.分析结果显示:1.与安慰剂相比,他喷他多组50%总反应有效率有显著差异(RR=1.31,95%CI(1.16,1.48,P〈0.0001);他喷他多治疗组的NRS评分平均改变量较安慰剂组改变显著[SMD=-0.37,95%CI(-0.54,-0.21),P〈0.0001];2.亚组分析结果显示:在治疗腰疼、关节痛等躯体疼痛和DPNP方面,他喷他多疗效显著优于安慰剂组(P〈0.0001);3.他喷他多的试验总终止率显著低于安慰剂;因不良事件发生率高于安慰剂组[OR=1.28,95%CI(1.20,1.36),P〈0.0001],其中胃肠、恶心、呕吐、及便秘的发生率均高于安慰组.结论他喷他多在治疗慢性非癌性疼痛疗效显著优于安慰剂,但是有-定的安全性问题.
出处 《中华临床医师杂志(电子版)》 CAS 2016年第11期218-220,共3页 Chinese Journal of Clinicians(Electronic Edition)
基金 国家“重大新药创制”科技重大专项资助项目(2012ZX09102101-010)
  • 相关文献

参考文献4

二级参考文献46

  • 1US FDA. FDA approves new drug to alleviate moderate to severe pain [ EB/OL ] [2008 - 11 - 24]. http://www, fda. gov/bbs/ topics/NEWS/2008/NEW01916, html.
  • 2TZSCHENTKET M, de VRY J, TERLINDEN R, et al. Tapentadol hydrochloride[ J ]. Drugs Future,2006,31 ( 12 ) : 1053 - 1061.
  • 3KALSO E, EDWARDS J E, MOORE R A, et al. Opioids in chronic non-cancerpain: systematic review of efficacy and safety[ J ]. Pain ,2004,112 ( 3 ) :372 - 380.
  • 4TZSCHENTKE T M, CHRISTOPH T, KOEGEL B, et al. ( - ) -( IR, 2R ) -3-( 3-dimethylamino-l-ethyl-2-methyl-propyl) -phenolhydrochloride ( tapentadol HCI) : a novel μ-opioid receptor agonist/norepinephrine reuptake inhibitor with broad- spectrum analgesic properties [ J ]. J Pharmacol Exp Ther, 2007,323 ( 1 ) :265 - 276.
  • 5TERLINDEN R, OSSIG J, FLIEGERT F, et al. Absorption, metabolism, and excretion of ^14 C-labeled tapentadol HCI in healthy male subjects [ J ]. Eur J Drug Met Pharmacokin, 2007,32 (3) : 163 - 169.
  • 6[1]Terlinden R,Ossig J,Fliegert F,et al.Absorption,metabolism,and excretion of 14C-labeled tapentadol HCl in healthy male subjects-Eur J Drug Metabol Pharmacokinet,2007,32 (3):163-169.
  • 7[2]Tzschentke TM,Vry JD,Terlinden R,et al.Tapentadol hydrochloride:Analgesic mu-opioid receptor agonist noradrenaline reuptake inhibitor.Drugs Fur,2006,31 (12):1053-1061.
  • 8[3]Tzschentke TM,Christoph T,Kogel B,et al.(-) -(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCI):a novel μ opioid receptor agonist/norepinephrine reuptake inhibitor with broad spectrum analgesic properties.J Pharmacol Exp Ther,2007,323 (1):265-269.
  • 9[4]Weber H,Hallman C,Steup A,et al.Efficacy and safety of tapentadol HCl in patients with pain after bunionectomy.J Pain,2006,7 Suppl 1,S3:312/776.
  • 10[5]Kleinert R,Hallmann C,Steup A,et al.Efficacy of a single dose of tapentadol HCl for analgesia after third molar surgery.J Pain,2006,7 suppl 1,S44:773.

共引文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部